| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | NEUTRAL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 15.46▼ | 15.63▼ | 15.62▼ | 16.31▼ | 20.92▼ |
| MA10 | 15.56▼ | 15.64▼ | 15.61▼ | 16.91▼ | 20.13▼ |
| MA20 | 15.62▼ | 15.63▼ | 15.96▼ | 20.96▼ | 15.56▼ |
| MA50 | 15.63▼ | 16.27▼ | 16.46▼ | 19.89▼ | 14.69▲ |
| MA100 | 15.62▼ | 16.52▼ | 19.24▼ | 15.48▼ | 11.48▲ |
| MA200 | 15.97▼ | 19.67▼ | 22.67▼ | 14.58▲ | 10.19▲ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.028▼ | 0.033▲ | 0.010▲ | -0.872▼ | 0.216▲ |
| RSI | 39.064▼ | 38.975▼ | 37.086▼ | 35.294▼ | 48.203▼ |
| STOCH | 10.638▼ | 60.324 | 66.733 | 17.295▼ | 58.171 |
| WILL %R | -84.286▼ | -49.239 | -63.768 | -94.268▼ | -73.203 |
| CCI | -117.271▼ | -161.454▼ | -134.438▼ | -74.732 | -15.553 |
|
Friday, November 14, 2025 02:37 AM
It certainly might concern ClearPoint Neuro, Inc. ( NASDAQ:CLPT ) shareholders to see the share price down 40% in ...
|
|
Thursday, November 13, 2025 10:25 AM
Detailed price information for Clearpoint Neuro Inc (CLPT-Q) from The Globe and Mail including charting and trades.
|
|
Wednesday, November 12, 2025 11:54 AM
The near-term outlook for ClearPoint's biopharma business is also now clouded by FDA uncertainty around uniQure's AMT-130. Click to read why CLPT is a Buy.
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 14/11/25 | 14.92 | 16.00 | 14.92 | 15.43 | 591,101 |
| 13/11/25 | 16.51 | 16.51 | 15.4316 | 15.50 | 665,037 |
| 12/11/25 | 17.43 | 17.65 | 16.2901 | 16.71 | 553,698 |
| 11/11/25 | 16.60 | 17.78 | 16.00 | 17.40 | 991,512 |
| 10/11/25 | 16.58 | 17.11 | 15.83 | 16.53 | 1,042,005 |
| 07/11/25 | 14.97 | 16.24 | 14.71 | 15.81 | 2,049,439 |
| 06/11/25 | 17.12 | 18.71 | 16.59 | 18.23 | 1,751,347 |
| 05/11/25 | 17.67 | 17.76 | 16.90 | 16.98 | 960,453 |
| 04/11/25 | 17.57 | 18.5395 | 17.15 | 17.52 | 1,239,327 |
| 03/11/25 | 16.355 | 19.68 | 15.56 | 19.00 | 4,299,698 |
|
|
||||
|
|
||||
|
|